PHARMACY

Study finds Atrovent increases risk of cardiovascular death

BY Alaric DeArment

HINES, Ill. Patients with chronic obstructive pulmonary disease who take the drug ipratropium bromide for preventing bronchospasm increased their risk of death from cardiovascular causes, according to a study published Tuesday in the Annals of Internal Medicine.

The researchers found that use of the drug, which Boehringer Ingelheim markets under the brand name Atrovent, increased the risk of cardiovascular death by 34 percent. Also, exposure to theophylline caused a statistically significant increase in deaths from respiratory problems, though there was no relationship between theophylline and cardiovascular death.

At the same time, however, use of corticosteroid inhalants reduced the risk of cardiovascular death and death from other causes by about 20 percent.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

The Little Clinic opens two more Florida locations

BY Antoinette Alexander

BRENTWOOD, Tenn. The Little Clinic has opened new clinics at Publix stores located in Tampa and Deerfield Beach in South Florida.

The new Deerfield Beach clinic is the 11th location opened by The Little Clinic in South Florida.

The new clinic in Tampa marks the 12th location in the Tampa area to open within Public.

The clinic operator did not disclose further details but did say that additional clinics are under construction in both Tampa and South Florida.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA denies approval for Fentora non-cancer treatment

BY Alaric DeArment

BOSTON The Food and Drug Administration has denied approval for Cephalon to market Fentora for treating pain not related to cancer, the company announced Monday.

The opioid painkiller is approved for treating breakthrough pain in some cancer patients, but the company applied for FDA approval to market it for treating chronic back pain and neuropathic pain.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?